Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2018
Source ID
10.1016/j.bbmt.2017.09.013

Entities

People

  • Amer Beitinjaneh
  • Bipin N Savani
  • Brent R. Logan
  • Bronwen E Shaw
  • Christopher N. Bredeson
  • David F. Stroncek
  • Deidre M. Kiefer
  • Dennis L Confer
  • Dipnarine Maharaj
  • Galen E Switzer
  • Gregory A. Hale
  • Hillard M Lazarus
  • Hisham Abdel-azim
  • Ibrahim Ahmed
  • Jane L. Liesveld
  • Jean A. Yared
  • Jeffrey Szer
  • Joerg Halter
  • Kimberly Anne Kasow
  • Matthew Seftel
  • Michael A Pulsipher
  • Miguel Angel Diaz
  • Nirali Shah
  • Paolo Anderlini
  • Pashna N Munshi
  • Paul V. O'donnell
  • Peiman Hematti
  • Pintip Chitphakdithai
  • Richard F. Olsson
  • Sachiko Seo
  • Siddhartha Ganguly
  • Zachariah DeFilipp
  • Zheng Zhou

Organizations

  • Amgen
  • Angiocrine Bioscience (United States)
  • Astellas Pharma (United States)
  • AstraZeneca (United States)
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb
  • Celgene
  • Chiron Corporation
  • Fred Hutchinson Cancer Center
  • Genzyme
  • Gilead Sciences
  • Health Resources and Services Administration
  • Incyte
  • Janssen Scientific Affairs (United States)
  • Jazz Pharmaceuticals
  • Karyopharm Therapeutics (United States)
  • Kite Pharma
  • Medical College of Wisconsin
  • Merck & Co.
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Marrow Donor Program
  • Office of Naval Research
  • Otsuka Pharmaceutical
  • Patient-Centered Outcomes Research Institute
  • Pfizer
  • Seagen
  • Shire plc
  • Spectrum Pharmaceuticals
  • St. Baldrick's Foundation
  • Swedish Orphan Biovitrum
  • Takeda Oncology
  • University of Minnesota

Tags

Technology Areas

  • Biotechnology